Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic
paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target …

The von Hippel-Lindau (VHL) Cullin RING E3 ligase is an essential enzyme in the ubiquitin-
proteasome system that recruits substrates such as the hypoxia inducible factor for …

Chronic (continuous, non-interrupted) hypoxia and cycling (intermittent, transient) hypoxia
are two types of hypoxia occurring in malignant tumors. They are both associated with the …

Targeted protein degradation is a rapidly exploding drug discovery strategy that uses small
molecules to recruit disease-causing proteins for rapid destruction mainly via the ubiquitin …

Targeted protein degradation (TPD) has emerged as an exciting new era in chemical
biology and drug discovery. PROteolysis TArgeting Chimera (PROTAC) technology targets …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of
two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” to bind to a …

Targeted protein degradation as a therapeutic modality has seen dramatic progress and
massive investment in recent years because of the convergence of two key scientific …